Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CQ-527
- Development stage
- Preclinical
- Lead developer
- Protheragen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CQ-527 is a preclinical-stage small molecule tubulin inhibitor being developed by Protheragen for the treatment of cancer. Tubulin is a structural protein that polymerizes into microtubules, which are essential for maintaining cell shape, intracellular transport, and the formation of the mitotic spindle during cell division. By binding to tubulin, CQ-527 disrupts microtubule dynamics, typically leading to cell cycle arrest at the G2/M phase and subsequent apoptosis in rapidly proliferating malignant cells. The asset is currently part of Protheragen's portfolio of available projects for licensing and further development.
- Other names
- CQ-527CQ527CQ 527
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CQ-527.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CQ-527.